View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 14, 2021

GSK and iTeos partner to develop antibody for cancer treatment 

iTeos will receive an upfront payment of $625m and is eligible to get up to $1.45bn in potential milestone payments.

GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to jointly develop and market a monoclonal antibody, EOS-448, as a potential cancer treatment.

A human IgG1 antibody, EOS-448 is created to attach with high-affinity T cell immunoglobulin and ITIM domains (TIGIT). It has a multifaceted mechanism that induces an antitumor response.

According to the partnership terms, iTeos will get an upfront payment of $625m from GSK.

iTeos is also eligible for up to $1.45bn in potential milestone payments if the EOS-448 programme meets specific development and commercial milestones.

The worldwide development works of EOS-448 and expenses will be shared by both the companies, which will co-market the antibody in the US and split profits equally.

Furthermore, GSK will obtain an exclusive licence to market EOS-448 outside of the US and will pay tiered royalties to iTeos.

Adding EOS-448 data will aid GSK to become the only firm with antibodies that target all three known CD226 checkpoints – TIGIT via EOS-448, CD96 via GSK’608 and PVRIG via GSK’562.

Along with GSK’s approved anti-PD-1 therapy, Jemperli (dostarlimab), these potential immuno-oncology agents will be analysed in several new combinations to treat various cancer types.

GSK R&D president and chief scientific officer Dr Hal Barron said: “Immuno-oncology has transformed cancer care but unfortunately less than 30% of patients respond to treatment with the current leading immune checkpoint inhibitors.

“Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer.”

GSK and iTeos intend to commence trials of EOS-448 in combination with dostarlimab next year.

EOS-448 is presently in an open-label Phase I trial for treating advanced solid tumour patients.

iTeos president and CEO Michel Detheux said: “Inspired by the multifaceted mechanism of action of EOS-448 and promising early results in clinical trials, this collaboration allows us to accelerate and expand the clinical development of EOS-448.”

In February, GSK signed a binding agreement with Vir Biotechnology to expand its existing partnership to research and develop novel therapies for influenza and other respiratory viruses.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology